Related Experiment Video

Updated: Jul 26, 2026

Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein
05:51

Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein

Published on: January 13, 2026

199

Development and current clinical application of ventricular assist devices in China

Yue Wu1, Liang-Fan Zhu1, Yun Luo1

  • 1School of Mechanical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.

Journal of Zhejiang University. Science. B
|November 10, 2017
PubMed

Insights

Ventricular assist devices (VADs) offer a solution for heart failure when transplants are unavailable. This paper reviews the slow development of VADs in China, introducing domestic devices and discussing future challenges and opportunities.

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering
  • Medical Device Development

Background:

  • Heart failure is a significant global health concern, with limited donor hearts for transplantation.
  • Ventricular assist devices (VADs) are crucial for managing heart failure, but their development in China lags.
  • China faces a growing heart failure burden, necessitating advancements in VAD technology.

Purpose of the Study:

  • To examine the background and current status of VAD development in China.
  • To introduce domestically developed VADs and their clinical application.
  • To discuss the challenges and opportunities for VADs in China.

Main Methods:

  • Literature review of VAD development in China.
  • Introduction of specific Chinese-developed VADs.
  • Analysis of the current clinical application of VADs in China.

Main Results:

  • The development and clinical application of VADs in China are significantly slower compared to global trends.
  • Several Chinese-developed VADs have emerged, though widespread adoption is limited.
  • The paper details the current landscape of VADs within China.

Conclusions:

  • China's VAD sector faces significant challenges but also presents opportunities for growth.
  • Further development and clinical integration of VADs are crucial for addressing heart failure in China.
  • Addressing the slow development of VADs is essential for public health in China.

Keywords:
Ventricular assist devices; Heart failure; Clinical application

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

625
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

86

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...